To the full analysis
Sun Pharmaceutical Industries stock: growth
SUNPHARMA.NSSun Pharmaceutical Industries reported $6.21B in revenue for fiscal 2026, up 11.2% on the prior year, up 11.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
19%
per year from 2007 to 2026, per share 17.5%
Earnings (Annual rate)
14.8%
per year from 2007 to 2026, per share 13.7%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 11.8% | 7.6% | 19.0% |
| Revenue per share | 11.8% | 7.6% | 17.5% |
| Earnings | 31.6% | 9.3% | 14.8% |
| Earnings per share | 31.6% | 9.7% | 13.7% |
| Free cash flow | 13.1% | 10.6% | no data |
| Free cash flow per share | 13.1% | 10.6% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $226.61M | $89.3M | −$698.32K |
| 2008 | $356.76M | $164.84M | $32.14M |
| 2009 | $454.1M | $199.61M | $165.28M |
| 2010 | $414.94M | $143.17M | $54.11M |
| 2011 | $608.12M | $193.03M | $206.63M |
| 2012 | $850.45M | $274.99M | $173.81M |
| 2013 | $1.2B | $317.06M | $267.57M |
| 2014 | $1.71B | $333.9M | $324.52M |
| 2015 | $2.91B | $482.48M | $314.19M |
| 2016 | $2.99B | $501.25M | $359.99M |
| 2017 | $3.33B | $740.23M | $360.25M |
| 2018 | $2.81B | $229.75M | $206.88M |
| 2019 | $3.09B | $283.3M | −$108.03M |
| 2020 | $3.49B | $400.17M | $532.8M |
| 2021 | $3.56B | $308.64M | $531.47M |
| 2022 | $4.11B | $347.85M | $796.05M |
| 2023 | $4.66B | $900.64M | $305.45M |
| 2024 | $5.15B | $1.02B | $1.06B |
| 2025 | $5.59B | $1.16B | $1.27B |
| 2026 | $6.21B | $1.22B | $982.36M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.